Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Lung Cancer (Locally Advanced or Metastatic)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)UnknownNCT03274479
What this trial is testing

PBF-1129 in Patients With NSCLC

Who this might be right for
Locally Advanced or Metastatic NSCLC
Palobiofarma SL 18
Testing effectiveness (Phase 2)Study completedNCT01362296
What this trial is testing

An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer, Non-Small Cell
GlaxoSmithKline 134
Testing effectiveness (Phase 2)Study completedNCT03157089
What this trial is testing

Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 24
Testing effectiveness (Phase 2)UnknownNCT06590194
What this trial is testing

PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Suzhou Puhe Pharmaceutical Technology Co., LTD 96
Early research (Phase 1)Study completedNCT00506051
What this trial is testing

ZD6474(Vandetanib) + Alimta Combo Study

Who this might be right for
CarcinomaNon-Small Cell LungLung Cancer
Genzyme, a Sanofi Company 21
Testing effectiveness (Phase 2)Study completedNCT01633645
What this trial is testing

Bortezomib in Combination With Gemcitabine and Cisplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerMetastatic
University Hospital of Crete 53
Testing effectiveness (Phase 2)Looking for participantsNCT06616766
What this trial is testing

A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)Solid Tumor
Yuhan Corporation 201
Large-scale testing (Phase 3)Ended earlyNCT04427072
What this trial is testing

Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 22
Testing effectiveness (Phase 2)Study completedNCT00370292
What this trial is testing

Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non Small Cell Lung Cancer
Eli Lilly and Company 19
Large-scale testing (Phase 3)Not Yet RecruitingNCT07383116
What this trial is testing

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer

Who this might be right for
Non Squamous Non-small Cell Lung Cancer
Shanghai Huaota Biopharmaceutical Co., Ltd. 500
Large-scale testing (Phase 3)Study completedNCT00478049
What this trial is testing

Iressa as Second Line Therapy in Advanced NSCLC-Asia

Who this might be right for
NSCLC
AstraZeneca 163
Not applicableStudy completedNCT04207775
What this trial is testing

Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy

Who this might be right for
Locally Advanced or Metastatic NSCLC
AstraZeneca 300
Testing effectiveness (Phase 2)Study completedNCT01561456
What this trial is testing

Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung

Who this might be right for
Non-small-cell Lung CancerSquamous Cell CarcinomaAdenocarcinoma of the Lung
Axelar AB 100
Testing effectiveness (Phase 2)Ended earlyNCT04993391
What this trial is testing

AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer
Suzhou Junjing BioSciences Co., Ltd. 32
Testing effectiveness (Phase 2)Study completedNCT01138163
What this trial is testing

Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer

Who this might be right for
Non-small-cell Lung Cancer
Peregrine Pharmaceuticals 121
Early research (Phase 1)Active Not RecruitingNCT05653752
What this trial is testing

YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer

Who this might be right for
Non Small Cell Lung CancerBreast Cancer
MediLink Therapeutics (Suzhou) Co., Ltd. 80
Large-scale testing (Phase 3)Study completedNCT01774721
What this trial is testing

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Who this might be right for
Non-small Cell Lung Cancer With EGFR-Activating Mutations
Pfizer 452
Testing effectiveness (Phase 2)Study completedNCT02552121
What this trial is testing

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Who this might be right for
Ovary CancerCervix CancerEndometrium Cancer+4 more
Seagen Inc. 33
Testing effectiveness (Phase 2)Looking for participantsNCT07232849
What this trial is testing

A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer
Jiangsu HengRui Medicine Co., Ltd. 100
Testing effectiveness (Phase 2)Study completedNCT01529112
What this trial is testing

A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments

Who this might be right for
Non-Small Cell Lung Cancer
Eisai Inc. 135
Next Page